HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN


Solid Tumor Cell Therapy Combination Trial Cleared to Continue

There were no deaths or safety signals identified by the DSMB for the 3 treated patients in cohort 1.

Allogeneic CAR T Cleared for B-cell Malignancy Trials

Sana Biotechnology also plans to submit another IND for the same indications for a CD22-targeted CAR T later in 2022.

Advanced Colorectal Cancer CAR T Cleared for Trial

The phase 1 portion of the trial assessing CNA3103 will start enrollment in Australia in the first half of 2023; the phase 2 portion will expand to the US.